nutraceutical. New companies for ISF

Fedaisf editorial staff

March 4, 2018

Dr. Francesco Anatra, ISF, explains the mission of COhesion Pharma

Dr. Francis Duck, scientific informant of the company's drug COohesion Pharma, explains the mission of the Campania pharmaceutical cooperative: “Main goal – he underlines – is to achieve important results in nutraceuticals through completely natural products, with which we identify ourselves.

We also have the intention of creating new jobs through the possibility of marketing innovative products using the dynamics of the Pharmaceutical World. The most striking example of the success of our young cooperative is the Nurvast, a product useful in reducing cholesterol in "borderline" patients, who therefore have a level of LDL (low-density cholesterol, also called "bad cholesterol") between 200 and 260 mg\dL.

Furthermore, we sensitize the patient to a recovery process, diet first of all together with physical activity, assisted by nutraceutical products, without side effects, unlike what happens with the intake of statins, both synthetic and natural; the reference nutraceutical in the fight against the reduction of cholesterol levels, is la monacolin K, used as an alternative to statins, when cholesterol levels are not excessively high.

Nurvast, unlike statins or monacolin K, precisely because it derives from 100%, from a native apple from Campania, the annurca apple, does not cause side effects such as myalgia and fatigue. The mechanisms of action of Nurvast there are 3 of them and they do not intervene upstream of the inhibition reaction of dietary cholesterol absorption; therefore, there is no accumulation of metabolites in that phase, as occurs instead with statins and monacolin K which have the same mechanism of action.

At the basis of this great innovation are procyanidins, the natural active ingredient of Nurvast, extracted by centrifugation from the Annurca apple, a genuine Campania excellence”.

Note: Coohesion Pharma was born in 2016 from the aggregation of a group of Pharmaceutical Representatives from large pharmaceutical companies gathered in cooperatives.

Nutraceuticals, a healthy business that now lands on the stock exchange

Kolinpharma debutterà a piazza Affari entro il 12 marzo facendo da apripista a quell’ondata di quotazioni che avverrà nel 2018 per effetto dei pir, i piani individuali di risparmio partoriti dal Mef lo scorso anno. Una storia d’impresa

Of Mariarosaria Marchesano – 4 marzo 2018

Kolinpharma is a small Milanese company with major projects in the nutraceutical sector (the use of nutrition to have beneficial effects on health) will debut in Piazza Affari by 12 March, leading the way in that wave of quotations (about fifty, according to official estimates) which will take place in 2018 as a result of the pir, the individual savings plans created by the MEF last year.

In fact, the PIRs have collected so much liquidity (11 billion so far) to push banks and advisors to go hunting for Italian excellence to bring to the AIM, a list that allows access to the Stock Exchange through a simplified procedure and at reduced costs. Thus, in the great showcase of finance there is space for a young but innovative business history such as that of Kolinpharma, which has been able to intercept the growing interest of Italians, especially women, for those natural substances (for example turmeric and cranberry) which can replace or integrate medical therapies or be used as prevention.

Rita Paola Petrelli and Emanuele Lusenti, who founded the company in 2013, do not say how much was raised in the placement phase with investors that has just ended, but it must have gone more than well, both seem enthusiastic about having enough resources to be able to make a leap in quality. Yet, their project was born, almost by chance, at a high altitude. Rita Petrelli, who is from Calabria and is an accountant by profession, one day meets the Brescian manager Lusenti on a plane, a past as director of pharmaceutical companies such as Schiapparelli, Sigma Tao, Alfa Wassermann, Bracco, and, above all, a great desire to reinventing himself at fifty also to be closer to his wife who has some health problems.

Rita, in addition to extricating herself from budgets, has contacts with the University of Calabria, where in the botanical park managed by the Department of Biology - between Pollino, Aspromonte and Sila - rare species of herbs and plants are cultivated that are not have yet to be tested in nutraceuticals, a sector which in Italy sees around 2,000 companies active with a turnover of 3 billion which continues to grow. Emanuele, for his part, has the right wealth of knowledge to organize a distribution network and how to set up the relationship with scientific representatives, who make the difference in this field.

The company that takes shape in a short time. Registered office in via Larga, in Milan, and operational headquarters in the pharmaceutical industrial hub of Lainate-Origgio. The hiring of six researchers and managers makes the structure operational in 2015. Two years later, at the end of 2017, Kolinpharma's turnover is 4 million and it is clear that there is ample room for growth that only new investments in research and development can to support.

“Before a natural essence can become a therapeutic support, its effectiveness must be verified through clinical tests and accreditation procedures”, explains Rita Petrilli, “We have five types of products on the market, six patent applications and four certificates already obtained".

And on the horizon, there is unexplored potential. “Today this sector is very popular with the Muslim public, who prefer products that exclude the use of meat and alcohol”, says Lusenti who has in mind an international expansion for Kolinpharma.